Giuseppina Rosaria Rita Ricciardi
Overview
Explore the profile of Giuseppina Rosaria Rita Ricciardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi G, Silvestris N, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628975
HER2-low and ultra-low breast cancer (BC) have been recently proposed as new subcategories of HER2 BC, supporting a re-consideration of immunohistochemical negative scores of 0, 1+ and the 2+/in situ...
2.
Colombo N, Gadducci A, Landoni F, Lorusso D, Sabbatini R, Artioli G, et al.
Gynecol Oncol
. 2023 Jun;
175:182-189.
PMID: 37355448
Introduction: Standard treatment of newly diagnosed, advanced ovarian carcinoma (OC) consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has...
3.
Puliafito I, Chillari F, Russo A, Cantale O, Sciacca D, Castorina L, et al.
Front Endocrinol (Lausanne)
. 2023 Feb;
14:1065599.
PMID: 36793289
Background: Lung neuroendocrine neoplasms (NENs) are rare malignancies developed from bronchial mucosa. Because of its rarity and complex histopathology, there is limited data on the role of chemotherapy in this...
4.
Adamo V, Ricciardi G, Giuffrida D, Scandurra G, Russo A, Blasi L, et al.
Ther Adv Med Oncol
. 2020 Jan;
11:1758835919895755.
PMID: 31903098
Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre,...
5.
Adamo B, Ricciardi G, Ieni A, Franchina T, Fazzari C, Sano M, et al.
Oncotarget
. 2019 Feb;
10(8):917.
PMID: 30783520
[This corrects the article DOI: 10.18632/oncotarget.20293.].
6.
Ricciardi G, Russo A, Franchina T, Schifano S, Mastroeni G, Santacaterina A, et al.
BMC Cancer
. 2018 Jan;
18(1):97.
PMID: 29370839
Background: Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement....
7.
Adamo B, Ricciardi G, Ieni A, Franchina T, Fazzari C, Sano M, et al.
Oncotarget
. 2017 Nov;
8(44):76974-76986.
PMID: 29100362
Background: Triple Negative Breast Cancer (TNBC) represents a heterogeneous group of tumors with poor prognosis owing to aggressive tumor biology and lack of targeted therapies. No clear prognostic biomarkers have...
8.
Picciotto M, Franchina T, Russo A, Ricciardi G, Provazza G, Sava S, et al.
Expert Opin Pharmacother
. 2017 Apr;
18(9):899-908.
PMID: 28449621
During the last few years, the therapeutic armamentarium of castration resistant prostate cancer (mCRPC) has been enriched with the introduction of new effective therapies with proved survival benefit and quality...
9.
Russo A, Franchina T, Ricciardi G, Fanizza C, Scimone A, Chiofalo G, et al.
Oncotarget
. 2017 Jan;
8(5):8717-8725.
PMID: 28060728
Epidermal Growth Factor Receptor (EGFR) mutated Non Small Cell Lung Cancers (NSCLCs) are a molecularly subgroup of patients with peculiar clinic-pathological characteristics. Previous studies have suggested a possible interaction between...
10.
Russo A, Franchina T, Ricciardi G, Adamo V
J Thorac Oncol
. 2016 Dec;
12(1):e6-e8.
PMID: 27988103
No abstract available.